Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number: 3235-02											
Estimated average burden											
hours per response:											

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hooks Corwin Dale				2. Issuer Name and Ticker or Trading Symbol Applied Therapeutics, Inc. [APLT]								ck all app Direc	tor	ng Pers	10% Ov	ner			
(Last)	(Fi	rst) (MERAPEUTICS, I	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/12/2024)	belov	er (give title v) nief Comm	nercial	Other (s below)	pecify	
545 FIFTH AVENUE, SUITE 1400				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) NEW YORK NY 10017) 	_	filed by One filed by Mo on		J	- 1	
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication														
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												ided to		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Dat			Date	Date (Month/Day/Year) Exec		Deemed ecution Date, ny onth/Day/Year)					s Acquired (A) or f (D) (Instr. 3, 4 a				ties cially I Following	Form:	Direct of Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount (/) or)	Price		saction(s) c. 3 and 4)		[Instr. 4)	
Common Stock 04			04/12/2	/2024			A		300,000(1)	A	\$ <mark>0</mark>	300,000			D			
					ive Securities Acquired, Disposed of, or Benefic its, calls, warrants, options, convertible securiti														
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, Trans ty or Exercise (Month/Day/Year) if any Code			Transa Code (saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		str.	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y D o (I	0. Dwnership orm: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amour or Number of Title Shares						

Explanation of Responses:

1. Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One fourth (1/4th) of the compensatory Restricted Stock Units shall vest on April 12, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date.

/s/ Shoshana Shendelman, as attorney-in-fact

04/15/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.